Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MUSASHI-2 confers resistance to third-generation EGFR-tyrosine kinase inhibitor osimertinib in lung adenocarcinoma.

Cancer science - 1 Sept 2021

Yiming Reheman, Takeuchi Yasuto, Nishimura Tatsunori, Li Mengjiao, Wang Yuming, Meguro-Horike Makiko, Kohno Takashi, Horike Shin-Ichi, Nakata Asuka, Gotoh Noriko

Abstract excerpt

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are effective in patients with non-small-cell lung cancer (NSCLC) harboring EGFR mutations. However, due to acquired resistance to EGFR-TKIs, even patients on third-generation osimertinib have a poor prognosis. Resistance mechanisms are still not fully understood. Here, we demonstrate that the increased expression of MUSASHI-2 (MSI2), an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to A549 Cells
Share to Acrylamides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Adenocarcinoma of Lung

Share to Aniline Compounds

Share to Gefitinib

Share to Gene Knockdown Techniques

Share to Nanog Homeobox Protein

Share to RNA-Binding Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 34145929
DOI: 10.1111/cas.15036
PMCID: PMC8409425

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MUSASHI-2 confers resistance to third-generation EGFR-tyrosine kinase inhibitor osimertinib in lung adenocarcinoma.PMID 34145929Read ↗

Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer.Semantic proximity Read ↗

Musashi 2 contributes to the stemness and chemoresistance of liver cancer stem cells via LIN28A activation.Semantic proximity Read ↗

Autophagy determines osimertinib resistance through regulation of stem cell-like properties in EGFR-mutant lung cancerSemantic proximity Read ↗

Regulation of lung cancer initiation and progression by the stem cell determinant MusashiSemantic proximity Read ↗

SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemnessSemantic proximity Read ↗

EREG increases stemness associated genes expression and promotes Chemoresistance of non-small cell lung cancer via ERK signalingSemantic proximity Read ↗

Aberrant m5C hypermethylation mediates intrinsic resistance to gefitinib through NSUN2/YBX1/QSOX1 axis in EGFR-mutant non-small-cell lung cancerSemantic proximity Read ↗

Epiregulin increases stemness-associated genes expression and promotes chemoresistance of non-small cell lung cancer via ERK signalingSemantic proximity Read ↗

ID1 mediates resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer through epithelial-mesenchymal transition.Semantic proximity Read ↗

NF-κB-driven improvement of EHD1 contributes to erlotinib resistance in EGFR-mutant lung cancersSemantic proximity Read ↗

Activation of LncRNA HOTAIR by STAT3 Promotes Gefitinib Resistance and Tumourigenesis by Targeting MicroRNA-216a in NSCLCSemantic proximity Read ↗

Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.